Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Repurposing anthelmintic agents to eradicate resistant leukemia

C. Mezzatesta, L. Abduli, A. Guinot, C. Eckert, D. Schewe, M. Zaliova, L. Vinti, B. Marovca, YC. Tsai, S. Jenni, J. Aguade-Gorgorio, A. von Stackelberg, M. Schrappe, F. Locatelli, M. Stanulla, G. Cario, JP. Bourquin, BC. Bornhauser

. 2020 ; 10 (6) : 72. [pub] 20200626

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21020437

Despite rapid progress in genomic profiling in acute lymphoblastic leukemia (ALL), identification of actionable targets and prediction of response to drugs remains challenging. To identify specific vulnerabilities in ALL, we performed a drug screen using primary human ALL samples cultured in a model of the bone marrow microenvironment combined with high content image analysis. Among the 2487 FDA-approved compounds tested, anthelmintic agents of the class of macrocyclic lactones exhibited potent anti-leukemia activity, similar to the already known anti-leukemia agents currently used in induction chemotherapy. Ex vivo validation in 55 primary ALL samples of both precursor B cell and T-ALL including refractory relapse cases confirmed strong anti-leukemia activity with IC50 values in the low micromolar range. Anthelmintic agents increased intracellular chloride levels in primary leukemia cells, inducing mitochondrial outer membrane depolarization and cell death. Supporting the notion that simultaneously targeting cell death machineries at different angles may enhance the cell death response, combination of anthelmintic agents with the BCL-2 antagonist navitoclax or with the chemotherapeutic agent dexamethasone showed synergistic activity in primary ALL. These data reveal anti-leukemia activity of anthelmintic agents and support exploiting drug repurposing strategies to identify so far unrecognized anti-cancer agents with potential to eradicate even refractory leukemia.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020437
003      
CZ-PrNML
005      
20210830102124.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41408-020-0339-9 $2 doi
035    __
$a (PubMed)32591499
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mezzatesta, Caterina $u Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
245    10
$a Repurposing anthelmintic agents to eradicate resistant leukemia / $c C. Mezzatesta, L. Abduli, A. Guinot, C. Eckert, D. Schewe, M. Zaliova, L. Vinti, B. Marovca, YC. Tsai, S. Jenni, J. Aguade-Gorgorio, A. von Stackelberg, M. Schrappe, F. Locatelli, M. Stanulla, G. Cario, JP. Bourquin, BC. Bornhauser
520    9_
$a Despite rapid progress in genomic profiling in acute lymphoblastic leukemia (ALL), identification of actionable targets and prediction of response to drugs remains challenging. To identify specific vulnerabilities in ALL, we performed a drug screen using primary human ALL samples cultured in a model of the bone marrow microenvironment combined with high content image analysis. Among the 2487 FDA-approved compounds tested, anthelmintic agents of the class of macrocyclic lactones exhibited potent anti-leukemia activity, similar to the already known anti-leukemia agents currently used in induction chemotherapy. Ex vivo validation in 55 primary ALL samples of both precursor B cell and T-ALL including refractory relapse cases confirmed strong anti-leukemia activity with IC50 values in the low micromolar range. Anthelmintic agents increased intracellular chloride levels in primary leukemia cells, inducing mitochondrial outer membrane depolarization and cell death. Supporting the notion that simultaneously targeting cell death machineries at different angles may enhance the cell death response, combination of anthelmintic agents with the BCL-2 antagonist navitoclax or with the chemotherapeutic agent dexamethasone showed synergistic activity in primary ALL. These data reveal anti-leukemia activity of anthelmintic agents and support exploiting drug repurposing strategies to identify so far unrecognized anti-cancer agents with potential to eradicate even refractory leukemia.
650    _2
$a zvířata $7 D000818
650    _2
$a anthelmintika $x farmakologie $x terapeutické užití $7 D000871
650    _2
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a apoptóza $x účinky léků $7 D017209
650    12
$a přehodnocení terapeutických indikací léčivého přípravku $7 D058492
650    _2
$a chemorezistence $7 D019008
650    _2
$a lidé $7 D006801
650    _2
$a myši SCID $7 D016513
650    _2
$a akutní lymfatická leukemie $x farmakoterapie $x patologie $7 D054198
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a nádorové mikroprostředí $x účinky léků $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Abduli, Liridon $u Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
700    1_
$a Guinot, Anna $u Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
700    1_
$a Eckert, Cornelia $u Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany $u German Cancer Consortium (DKTK), Berlin, Germany
700    1_
$a Schewe, Denis $u Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
700    1_
$a Zaliova, Marketa $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Vinti, Luciana $u Department of Pediatric Haemato-Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy
700    1_
$a Marovca, Blerim $u Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
700    1_
$a Tsai, Yi-Chien $u Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
700    1_
$a Jenni, Silvia $u Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
700    1_
$a Aguade-Gorgorio, Julia $u Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
700    1_
$a von Stackelberg, Arend $u Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany $u German Cancer Consortium (DKTK), Berlin, Germany
700    1_
$a Schrappe, Martin $u Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
700    1_
$a Locatelli, Franco $u Department of Pediatric Haemato-Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy
700    1_
$a Stanulla, Martin $u Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
700    1_
$a Cario, Gunnar $u Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
700    1_
$a Bourquin, Jean-Pierre $u Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland
700    1_
$a Bornhauser, Beat C $u Department of Oncology and Children's Research Center, Children's Hospital Zurich, Lengghalde 5, Balgrist Campus AG, 8008, Zurich, Switzerland. beat.bornhauser@kispi.uzh.ch
773    0_
$w MED00187996 $t Blood cancer journal $x 2044-5385 $g Roč. 10, č. 6 (2020), s. 72
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32591499 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102125 $b ABA008
999    __
$a ok $b bmc $g 1691082 $s 1140883
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c 6 $d 72 $e 20200626 $i 2044-5385 $m Blood cancer journal $n Blood Cancer J $x MED00187996
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options